Top Highlights From the 2015 AACR Annual Meeting
This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.
REFERENCES1. Jameson GS, Borazanci E, Poplin E, et al. High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract LB-003.2. Ribas A, Schachter J, Long GV, et al. Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract CT101.3. Hodi FS, Postow MA, Chesney J, et al. Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract 2860.4. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract 2859.5. Mateo J, Sandhu S, Miranda S, et al. DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract CT322.6. Beachler DC, Kreimer AR, Schiffman M, et al. Efficacy of the HPV16/18 vaccine against cervical, anal, and oral HPV infection among women with and without previous HPV16/18 exposure. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract 4680.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa69f69efca1ade2e100fbb9cdf798d49ea5a0f94-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.")
